Panntherapi

Acting on an innovative and specific target, we are developing a more efficient and safer treatment for pediatric patients with a resistant epilepsy, representing a B$1.5 EU & US market; by using a well-known molecule screened on post-operative brain tissues from targeted patients and reformulated to be adapted to the pediatric population, we are decreasing risk and accelerating access to the market (licensing to a pharma in 2026).

Panntherapi aims to treat epilepsy in a specific manner, acting on a new mode of action: the activated pannexin 1 channel. This target was identified using post-operative brain tissues from epileptic patients and our team demonstrated that the Panx1 channel is 1) overexpressed in pathological tissue; 2) activated under pathological conditions; 3) involved in the seizure genesis via its activation. Our first drug, directly tested on post-operative brain tissues from targeted patients and in a mice model of resistant epilepsy, blocks >80% of seizures with no impact on other cognitive processes.

From an innovation of the Collège de France and protected by 2 patents, our first candidate is a repurposed and reformulated (long release pediatric formulation) drug which can be tested next year in patients with an orphan resistant epileptic syndrome (>70% of drug resistance), giving access to the orphan drug designation (supplementary market protection: 10 years in EU, 7 in US). The product will be then licensed to a pharma in 2026 (discussion started).